A UK COST-UTILITY ANALYSIS OF PACLITAXEL ALBUMIN COMPARED TO SOLVENT-BASED PACLITAXEL MONOTHERAPY AND DOCETAXEL MONOTHERAPY FOR PRETREATED METASTATIC BREAST CANCER (MBC)

被引：4
|
作者：
McLeod, E. J. [1 ]
Lloyd, A. [1 ]
Samyshkin, Y. [1 ]
Prunieras, F. [2 ]
Canney, P. [3 ]
机构：
[1] IMS Hlth, London, England
[2] ABRAXIS BIOSCI, Paris, France
[3] Beatson W Scotland Canc Ctr, Glasgow, Lanark, Scotland
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)71991-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A269 / A269
页数：1
相关论文
共 50 条
  • [31] Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study
    Carrato, Alfredo
    Garcia, Pilar
    Lopez, Rafael
    Macarulla, Teresa
    Rivera, Fernando
    Sastre, Javier
    Gostkorzewicz, Joana
    Benedit, Patricia
    Perez-Alcantara, Ferran
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (04) : 579 - 589
  • [32] A cost-utility analysis of gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer.
    Ko, Yoo-Joung
    Tam, Vincent Channing
    Mittmann, Nicole
    Pasteka, Mark
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Randomized study comparing nab-paclitaxel with solvent- based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC)
    Guan, Z.
    Feng, F.
    Li, Q. L.
    Jiang, Z.
    Shen, Z.
    Yu, S.
    Feng, J.
    Huang, J.
    Yao, Z.
    Hawkins, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Cost-effectiveness of nanoparticle albumin-bound (nab) paclitaxel (ABX) vs Cremophor-based paclitaxel (CP) in the treatment of metastatic breast cancer (MBC).
    Gradishar, W
    Wolinsky, S
    Vishalpura, T
    Nightengale, B
    Bramley, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 36S - 36S
  • [35] Monotherapy with paclitaxel as third-line chemotherapy against anthracycline-pretreated and docetaxei-refractory metastatic breast cancer
    Kinoshita J.
    Haga S.
    Shimizu T.
    Imamura H.
    Watanabe O.
    Nagumo H.
    Utada Y.
    Okabe T.
    Kimura K.
    Hirano A.
    Kajiwara T.
    Breast Cancer, 2002, 9 (2) : 166 - 169
  • [36] Retrospective analysis of patients with poor prognostic factors and metastatic breast cancer in a phase III study comparing nab-paclitaxel to solvent-based paclitaxel
    Camburn, T.
    Tjulandin, S.
    Davidson, N.
    O'Shaughnessy, J.
    Bhar, P.
    Gradishar, W.
    EJC SUPPLEMENTS, 2008, 6 (07): : 180 - 180
  • [37] Cost utility analysis of nab-paclitaxel weekly or q3w compared with docetaxel q3w as first-line therapy in metastatic breast cancer (MBC)
    Dranitsaris, G.
    Perayre Badia, M.
    Clopes, A.
    Fernandez Ortega, M.
    Rey Salido, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB plus ANASTROZOLE COMPARED TO LAPATINIB plus LETROZOLE, LETROZOLE MONOTHERAPY OR ANASTROZOLE MONOTHERAPY IN THE TREATMENT OF HER2+/HORMONE RECEPTOR POSITIVE (HR plus ) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)
    McNamara, S.
    Moore, L.
    Ray, J.
    VALUE IN HEALTH, 2010, 13 (07) : A269 - A269
  • [39] Survival and cost-effectiveness of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer (MBC): A population-based evaluation.
    Vu, T. T.
    Ellard, S.
    Olivotto, I.
    Taylor, S. C.
    De Lemos, M. L.
    Speers, C.
    Kuik, K.
    Hu, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 329S - 329S
  • [40] Cost-effectiveness analysis of capecitabine in combination with docetaxel in comparison to docetaxel monotherapy in advanced or metastatic breast cancer in France
    Priol, G
    Maurel, F
    Le Pen, C
    BULLETIN DU CANCER, 2005, 92 (09) : 809 - 816
12345